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This study aims to quantify and compare preferences 
of citizens from different European countries for vac-
cination programme characteristics during pandemics, 
caused by pathogens which are transmitted through 
respiratory droplets. Internet panel members, nation-
ally representative based on age, sex, educational 
level and region, of four European Union Member 
States (Netherlands, Poland, Spain, and Sweden, 
n = 2,068) completed an online discrete choice experi-
ment. These countries, from different geographical 
areas of Europe, were chosen because of the availabil-
ity of high-quality Internet panels and because of the 
cooperation between members of the project entitled 
Effective Communication in Outbreak Management: 
development of an evidence-based tool for Europe 
(ECOM). Data were analysed using panel latent class 
regression models. In the case of a severe pandemic 
scenario, vaccine effectiveness was the most impor-
tant characteristic determining vaccination preference 
in all countries, followed by the body that advises on 
vaccination. In Sweden, the advice of family and/or 
friends and the advice of physicians strongly affected 
vaccine preferences, in contrast to Poland and Spain, 
where the advice of (international) health authorities 
was more decisive. Irrespective of pandemic scenario 
or vaccination programme characteristics, the pre-
dicted vaccination uptakes were lowest in Sweden, 
and highest in Poland. To increase vaccination uptake 
during future pandemics, the responsible authorities 
should align with other important stakeholders in the 
country and communicate in a coordinated manner.
Introduction
In the past 100 years, there have been several large-
scale influenza outbreaks with worldwide impact. 
These include the 1918 influenza A(H1N1) pandemic 
that caused between 50 and 100 million deaths par-
ticularly in many healthy young adults [1], and more 
recently the 2009 influenza A(H1N1)pdm09 pandemic 
[2]. Though characteristics (such as clinical attack rates 
and pathogenicity) and occurrence of a next influenza 
pandemic are unpredictable, experts agree there will 
be future influenza pandemics [2-5].
The World Health Organisation (WHO) urged countries 
to develop or update national influenza preparedness 
plans in response to the avian influenza A(H5N1) pan-
demic threat in 2005 [6]. Such plans subsequently 
needed to be improved taking into account the les-
sons learnt from the response to the influenza A(H1N1)
pdm09 pandemic [4,7,8]. In addition, countries could 
learn from each other by sharing information and best 
practices [9].
Preventive measures are very important in limiting the 
spread of an influenza pandemic [10-12] and if avail-
able, vaccination constitutes the control cornerstone 
[13,14]. The success of mitigating influenza pandem-
ics depends on many factors, including national public 
health policies and the availability of vaccines, vaccine 
effectiveness, and the public’s willingness to get vacci-
nated. Unfortunately, vaccination coverage has proven 
to be (too) low across Europe during the influenza 
A(H1N1)pdm09 pandemic. Vaccination coverage among 
the general public of the European Union, Norway and 
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Iceland, varied between countries from 0.4% to 59% 
[15].
Countries within Europe differ from each other with 
regard to languages, cultures, public trust in health 
authorities, health system infrastructures, and pub-
lic health capabilities and capacities. Research has 
shown that implementing international guidelines at 
the local level can be a complex process [16]. Having 
insights into country-specific reasons to accept or 
decline pandemic influenza vaccination can facilitate 
the adaptation of preparedness plans, including vacci-
nation strategies, to the local situation [17].
Thus far, only a limited number of reports have focused 
on the comparison of pandemic influenza vaccination 
preferences between people of different European 
countries [18,19], and formal quantitative techniques 
such as discrete choice experiments (DCEs) [20,21] have 
not yet been used. The primary aim of this study was 
to quantify and compare the preferences of European 
citizens for vaccination programmes for future pan-
demics. Although we focus on influenza pandemics, 
we quantified vaccination programme preferences for 
any emerging or re-emerging large-scale infectious dis-
ease outbreak that spreads through respiratory drop-
lets. Our findings might therefore also be applicable 
to other respiratory infections than influenza, such 
as, for example, severe acute respiratory syndrome 
(SARS)-coronavirus (CoV) or Middle East Respiratory 
Syndrome (MERS)-CoV, should vaccines be available 
for these viruses in the future. A secondary aim was to 
calculate the expected uptake of vaccination under dif-
ferent pandemic scenarios. The approach and results 
might help health policymakers to improve pandemic 
preparedness plans and communication strategies, in 
order to make future vaccination programmes more 
successful.
Methods
Study population
We surveyed a representative sample of the general 
public (age 18 years and over) of countries from differ-
ent parts of Europe: eastern Europe (Poland), northern 
Europe (Sweden), southern Europe (Spain) and west-
ern Europe (Netherlands). These countries were cho-
sen because of the availability of high-quality Internet 
panels (i.e. panels that are ISO certified and/or follow 
international quality standards for market research) 
and also because of the cooperation between pro-
ject members of different work packages within the 
Effective Communication in Outbreak Management: 
development of an evidence-based tool for Europe 
(ECOM) project (www.ecomeu.info). The public health 
policies of the four included countries with respect to 
seasonal influenza and influenza A(H1N1)pdm09 are 
described in Table 1.
Discrete choice experiments
A DCE is a survey-based stated-preference methodol-
ogy that originates in mathematical psychology [22]. 
The method has been increasingly used in healthcare, 
whereby the number of published DCEs has increased 
from a mean of three per year in the period from 1990 
to 2000 to 45 per year between 2009 and 2012 [23]. 
In a DCE, the relative importance of characteristics 
(i.e. attributes) of a certain product or intervention 
is assessed by presenting a series of choice sets to 
respondents [20,21]. In each choice set, respondents 
are asked to choose a preferred alternative from a set 
Figure 1
Response to the survey to investigate public preferences 
for vaccination programmes during pandemics caused 
by pathogens transmitted through respiratory droplets, 
Netherlands, Poland, Spain, and Sweden, 2013
Number of panel members who 
received an invitation: N=7,272
- NL 1,083 - PL 1,730
- SP 2,186  - SE 2,273
Number of panel members who 
responded to the questionnaire 
(response rate): N=2,651 (36%)
Number of panel members who 
did not respond: N=4,621
- NL 406 - PL 1,081
- SP 1,559 - SE 1,575
Number of panel members who 
stopped before signing informed 
consent: N=117
 - NL 677 (63%)    - PL 649 (38%) 
- SP 627 (29%)    - SE 698 (31%)
Number of panel members included 
in the analysis  (completion rate): 
N=2,068 (78%)
 - NL 536 (79%)      - PL 510 (79%) 
- SP 512 (82%)       - SE 510 (73%)
- NL 19 - PL 40
- SP 20 - SE 38
Number of panel members who 
did not complete the whole 
questionnaire: N=427
- NL 110 - PL 89
- SP 88 - SE 140
Number of panel members 
excluded due to low response 
quality: N=39a
- NL 12 - PL 10
- SP 7 - SE 10
NL: Netherlands; PL: Poland; SE: Sweden; SP: Spain.
a Low response quality was defined as completing the survey in 
less than 4 min.
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of two or more hypothetical product or intervention 
alternatives with systematically varying attribute lev-
els [20,21].
Survey
The survey started with an explanation of the DCE exer-
cise. Next, respondents were asked to imagine that a 
large-scale emerging infectious disease, that started 
abroad, had spread to the country they lived in. It was 
stated that the disease spreads through respiratory 
droplets, that it was vaccine-preventable, and that vac-
cines were available in their country. Respondents then 
completed a series of choice sets, followed by ques-
tions about socio-demographic characteristics (includ-
ing previous vaccination experiences), and questions 
that assessed the perceived difficulty of the survey. 
The survey ended with an open question in which 
respondents were given the opportunity to comment 
on the survey.
In each choice set, a hypothetical pandemic scenario 
based on two disease variables (susceptibility to the 
disease (i.e. a number of 1,000 people will get sick) 
and severity of the disease (i.e. a number of the sick 
people will develop severe symptoms) was presented. 
Respondents were then asked to choose between 
three alternatives: no vaccination, vaccination A, and 
vaccination B. The vaccination was described by sev-
eral attributes, and the presented levels differed sys-
tematically between vaccination A and vaccination B. 
In the following choice sets, both the pandemic sce-
nario and the presented attribute levels for vaccination 
A and B differed. In order to select realistic, relevant 
and understandable attributes and attributes levels, 
we conducted a literature study, expert interviews, and 
focus group discussions. In addition, we closely coop-
erated with project members when selecting the attrib-
utes and levels. PubMed, Embase and Psychinfo were 
strategically searched for relevant research articles 
on vaccination preferences. Expert interviews (n = 9) 
were conducted with both national and international 
experts (physicians, researchers, policymakers) in the 
field of infectious diseases, vaccinations, preventive 
behaviour, and implementation of prevention. We con-
ducted eight focus group discussions with representa-
tives of the general population, of which four in the 
Netherlands, two in Poland, two with Spanish citizens 
during their temporary stay in the Netherlands, and 
two in Sweden. Eligible participants were recruited by 
research companies and via our network, using purpo-
sive sampling to ensure a diverse sample. The focus 
groups revealed that similar vaccination programme 
attributes and attribute levels could be included in the 
DCE for all countries (Table 2). It is not feasible to pre-
sent a single respondent with all the possible combi-
nations of the included attribute levels. We therefore 
generated a subset of 48 choice sets by minimizing the 
D-efficiency criterion using the software programme 
Ngene (ChoiceMetrics, version 1.1.1). The 48 choice 
sets were grouped in three different survey versions 
such that each block has (near) attribute level balance. 
Each respondent thus needed to answer 16 choice sets. 
For more information on this part of a discrete choice 
experiment, see e.g. Reed Johnson et al. [24].
Figure 2
Relative importance of vaccination programme attributes for respondents’ decision to get vaccinated in the case of mild and 
severe pandemic scenarios caused by pathogens transmitted through respiratory droplets, Netherlands, Poland, Spain, and 
Sweden, 2013 (n = 2,068)
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The percentages represent the proportion of someone’s preference that is based on that attribute (utility). A mild pandemic was defined as a 
pandemic in which 5% of the population gets the disease (pandemic scenario variable susceptibility), and 5% of the sick people developing 
severe symptoms (pandemic scenario variable severity). A severe pandemic was defined as a pandemic in which 20% of the population gets 
the disease (pandemic scenario variable susceptibility), and 75% of the sick people develop severe symptoms scenario variable (pandemic 
scenario variable severity).
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Table 1
Overview of seasonal influenza and influenza A(H1N1)pdm09 policies per country, Netherlands, Poland, Spain, and 
Sweden, 2009 and 2013
Influenza type and 
respective policies Netherlands Poland Spain Sweden
Seasonal influenza [ 58 ] 
Groups 
recommended 
for vaccination 
during the 2012/13 
influenza season
NA Children and adolescents, aged ≥ 6 months – < 18 years NA NA
Adults aged ≥ 60 years Adults aged ≥ 55 years Adults aged ≥ 65 yearsa Adults aged ≥ 65 years
Medical risk groupsb Medical risk groupsb Medical risk groupsb Medical risk groups
b
Pregnant women with 
medical conditions All pregnant women
All pregnant 
women
Pregnant women in 2nd or 3rd 
trimester
All HCWs All HCWs All HCWs
HCWs caring for persons 
who are severely 
immunocompromised
Payment scheme 
vaccine and 
administration 
during the 2012/13 
influenza season
National health service 
Employer pays for HCWs
Payment scheme vaccine itself: 
out-of-pocket; some employers pay 
for HCWs; local governmentc 
Payment scheme administration: 
out-of-pocket; some employers pay 
for HCWs; local governmentc
Regional health 
service
Regional health service; out-
of-pocket varies with regionsd 
Employer pays for HCWs
Vaccination 
coverage during the 
2012/13 influenza 
season
Overall adults aged ≥ 60 
years: 67.8%
Overall adults aged ≥ 65 years: 7.4% 
HCWs: 9.5%
Overall adults 
aged ≥ 65 years: 
57% 
HCWs: 22.9%
Overall adults aged ≥ 65 years: 
44%
2009 influenza A(H1N1)pdm09 pandemic [ 19 ] 
Groups 
recommended for 
vaccination during 
the pandemic period
Children aged ≥ 6 months 
– 4 years, and household 
members of babies up to 
the age of 6 months
Poland did not implement a 
vaccination programme during the 
influenza A(H1N1)pdm09
NA Recommended for all children aged ≥ 6 months – < 18 years
Adults aged ≥ 60 years NA NA Adults aged ≥ 18 years
Medical risk groupsb NA Medical risk groupsb Medical risk groups
b
Pregnant women in 2nd 
and 3rd trimester NA
All pregnant 
women All pregnant women
HCWs with close contact 
with patients NA All HCWs All HCWs
Vaccine brand Pandemrix, Focetria NA
Pandemrix, 
Focetria, and 
Panenza
Pandemrix
Vaccination sites
GPs, mass vaccination 
sites in community 
settings, Municipal Health 
Services (children and 
household contacts), and 
work environment
NA
GPs, hospital 
settings, and 
occupational health 
services
GPs, hospital settings, 
outpatient care clinics, 
occupational health services, 
mass vaccination sites
Payment scheme
Free of charge for all 
individuals recommended 
the vaccine
NA
Free of charge for 
all individuals 
recommended the 
vaccine
Free of charge for all 
individuals recommended the 
vaccine
Vaccination 
coverage during the 
pandemic period
Entire population: 30% 
Those at risk aged > 6 
months: 72% 
Pregnant women: 58% 
HCWs: 50%
NA
Entire population: 
27.1% 
Those at risk 
aged > 6 months: 
23.7% 
Pregnant women: 
9% 
HCWs: 11.6%
Entire population: 59%
GP: general practitioner; HCW: healthcare worker; NA: not applicable.
a Recommendation at the national level. However, 10 of 19 regions recommend vaccine for those ≥ 60 years.
b Medical risk groups include e.g. patients with chronic pulmonary, cardiovascular and renal diseases, metabolic disorders, and 
immunosuppression due to disease or treatment (we refer to [1] for more details).
c Local government reimbursement of cost of vaccine and administration for those ≥ 65 years of age.
d In some regions, the vaccine is charged a symbolic amount (ca 10 euros) for vaccine and vaccination.
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The survey was first developed in Dutch and subse-
quently tested using think-a-loud interviews (n = 5) and 
a pen-and-paper pilot (n = 29). This resulted in some 
minor changes to the layout and phrasing of the Dutch 
survey. To be able to use the survey in the other coun-
tries, some further changes to the survey were made. 
For example, we adapted country naming, and curren-
cies for the cost attribute based on Organisation for 
Economic Cooperation and Development (OECD) com-
parative price levels [25] of May 2013 [26]. Hereafter, 
the survey was translated into Polish, Spanish and 
Swedish. A second translator reviewed each translated 
survey. To minimise differences between the original 
Dutch and the translated versions of the survey and to 
check for inconsistencies, native speakers (speaking 
Dutch and the respective languages) translated each 
survey back into Dutch. In Spain, Sweden and Poland, 
we asked 30 respondents per country to complete the 
adapted and back-translated survey online and to give 
their suggestions for improvement. No suggestions 
were given. More details of the DCE for the current 
study have been described elsewhere [27].
Data collection
An ISO certified market research company (ISO 26362 
[28], ISO 20252 [29], and ISO 14001 [30]), was hired 
to administer the online survey. This company used 
their own panel to collect data in the Netherlands, 
while another company’s panels were used to collect 
data in the other three countries. Both companies fol-
low international quality standards for market research 
[31]. Panel members were emailed an URL to the sur-
vey. Quota sampling was used to ensure that samples 
were representative for each country based on age, 
sex, educational level and region. We aimed to have 
500 completed surveys per country in order to obtain 
reliable outcomes [32]. All respondents gave informed 
consent before participating in the study and received 
a small financial incentive in local currency for their 
contribution to the study from the research company. 
The amount differed per country according to what is 
Table 2
Attributes and attribute levels included in the survey investigating public preferences for vaccination programmes during 
pandemics caused by pathogens transmitted through respiratory droplets, Netherlands, Poland, Spain, and Sweden, 2013 
(n = 7 attributes)
Scenario variablesa Levels
Pandemic scenario variablesa
Susceptibility to the diseaseb 5%, 10%, 20%
Severity of the diseasec 5%, 25%, 50%, 75%
Vaccination programme attributesd
Effectiveness of the vaccine 30%, 50%, 70%, 90%
Safety of the vaccinee
Unknown, expected to be safe (reference level)
Unknown, no experience with similar vaccines yet
Advice regarding the vaccine
Family and/or friends recommend vaccination (reference level)
Family and/or friends discourage vaccination
Your doctor recommends vaccination
Your doctor discourages vaccination
Government and national institute of public health recommend vaccination
International organisations recommend vaccination
Media attention about the vaccinef
Traditional media positive (reference level)
Traditional media negative
Social and interactive media positive
Social and interactive media negative
Out-of-pocket costsg 0 euro, 50 euros, 100 euros
a The scenario variables were the same for all alternatives in one choice set.
b Defined as the proportion of population affected by the emerging disease, i.e. having symptoms.
c Defined as the proportion of the infected population that had severe symptoms or outcomes (death, life-threatening events, hospitalisation 
and severe or permanent disability).
d The attributes safety of the vaccine, advice about the vaccine and media attention about the vaccine were included in the latent class 
analysis as categorical variables.
e Safety of the vaccine with regard to long-term severe side effects (death, life-threatening events, hospitalisation, severe or permanent 
disability, or side effects leading to birth defects in an unborn fetus).
f Traditional media were defined as radio, newspapers and television. Social and interactive media were defined as blogs, Twitter and social 
network websites.
g The levels presented in the Table are the selected levels for the Netherlands. Levels for the out-of-pocket costs attribute were converted to 
local currency of the other three countries and adapted according to the Organisation for Economic Co-operation and Development (OECD) 
price levels of May 2013 [26]. Levels of: 0 zloty, 120 zlotys, 240 zlotys for Poland; 0 euro, 45 euros and 90 euros for Spain and 0 kronor, 500 
kronor, 1,000 kronor for Sweden.
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customary in the given country (e.g. Dutch respond-
ents were paid 2.20 euros). Data collection took place 
between June and September 2013. A declaration of 
no objection was received from the Medical Ethics 
Committee of the Erasmus MC, University Medical 
Center Rotterdam (MEC-2012-263) after they reviewed 
the study protocol. According to Dutch legislation, the 
methodology of this study, a survey among volunteers 
of Internet panels, does not fall within the scope of the 
Medical Research Involving Human Subjects Act [33]. 
Although the aim of the study is of medical nature, 
respondents are not being subjected to any treatment 
or behavioural adjustments.
Data analysis
The choice observations resulting from the DCE were 
used to estimate the impact of pandemic scenario 
variables and vaccination programme attributes (inde-
pendent variables) on the respondents’ choices for 
vaccination or opting-out (dependent variable). A sig-
nificant independent variable in this choice model 
indicates that the attribute or attribute level has a 
significant impact on vaccination preferences and the 
Table 3
Characteristics of respondents who completed the survey per country, Netherlands, Poland, Spain, and Sweden, 2013 
(n = 2,068)
Characteristics Netherlands (n = 536)
Poland 
(n = 510)
Spain 
(n = 512)
Sweden 
(n = 510)
Age median (IQ range) 50 (35–64) 41 (28–55) 45 (31–57) 50 (35–59) 
N % %a N % %a N % %a N % %a 
Age groups (years)
      18–24 49 9.1 11 95 19 14 59 12 10 58 11 11 
      25–34 78 15 16 95 19 19 95 19 21 69 14 16 
      35–44 84 16 19 101 20 16 97 19 20 77 15 18 
      45–54 107 20 19 90 18 20 79 15 16 112 22 16 
      ≥55 218 41 35 129 25 30 182 36 33 194 38 39 
Sex (male) 289 54 49 261 51 48 251 49 49 245 48 49 
Country of birth is the country of interest 517 96 NA 502 98 NA 466 91 NA 440 86 NA 
Educational levelb
   Lower education 184 34 34 224 44 52 117 23 23 167 33 33 
   Average education 192 36 40 199 39 34 156 30 31 179 35 34 
   Higher education 160 30 26 87 17 14 239 47 46 164 32 33 
Incomec
   Low income 106 20 NA 133 26 NA 93 18 NA 120 24 NA 
   Average income 127 24 NA 127 25 NA 239 47 NA 256 50 NA 
   High income 181 34 NA 250 49 NA 180 35 NA 134 26 NA 
   Do not know or do not want to say 122 23 NA 0 0 NA 0 0 NA 0 0 NA 
Religious (yes) 244 46 NA 403 79 NA 250 49 NA 191 37 NA 
Working in healthcare (yes) 56 10 NA 20 4 NA 33 6 NA 48 9 NA 
Perception of own health
   Worse health than average 41 8 NA 40 8 NA 36 7 NA 44 9 NA 
   Medium health 195 36 NA 165 32 NA 214 42 NA 151 30 NA 
   Better health than average 300 56 NA 305 60 NA 262 51 NA 315 62 NA 
Seasonal influenza vaccine target group
   Yes 239 45 NA 85 17 NA 168 33 NA 136 27 NA 
   No 270 50 NA 382 75 NA 300 59 NA 321 63 NA 
   No, but receives vaccination via work 27 5 NA 43 8 NA 44 9 NA 53 10 NA 
Received seasonal influenza vaccination last year (yes, for 
persons belonging to target group) 156 65 NA 34 40 NA 97 58 NA 56 41 NA 
IQ: interquartile; NA: not applicable.
a Census data per country.
b Higher education was defined as: college, university, graduate degree; average education as: completed high school; and lower education 
as: all else, such as only elementary school or vocational education.
c Income was defined as: low (< 23,000 euros), average (23,000–34,000 euros), high (> 34,000 euros) per year for the Dutch sample; low 
(< 2,000 zlotys), average (2,000–3,000 zlotys), high (> 3,000 zlotys) per month for the Polish sample; low (< 999 euros), average (1,000–
2,000 euros),high (> 2,000 euros) per month for the Spanish sample; and low (< 175,000 kronor), medium (175,000–500,000 kronor), high 
(> 500,000 kronor) per year for the Swedish sample.
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Table 4
Regression coefficients for three latent classes based on responses to a survey investigating public preferences for vaccination 
programmes during pandemics caused by pathogens transmitted through respiratory droplets, Netherlands, Poland, Spain, 
and Sweden, 2013 (n = 2,068)a,b,c
Parameters
Class 1 Class 2 Class 3
Coefficient 
(p-value) SE 
Coefficient 
(p-value) SE 
Coefficient 
(p-value) SE 
Choice model 
Constant (vaccination) 0.70 (***) 0.04 -0.79 (***) 0.03 -5.02 (***) 0.27
Effectiveness of vaccination (per 10%) 0.18 (***) 0.01 -0.03 (***) 0.01 0.06 (NS) 0.05
Side effects unknown, but expected to be safe (reference) 0.16 (Ref) 0.01 0.17 (Ref) 0.01 0.22 (Ref) 0.08
Side effects unknown, no experience yet -0.16 (***) 0.01 -0.17 (***) 0.01 -0.22 (***) 0.08
Family and/or friends recommend (reference)d -0.22 (Ref) 0.02 -0.14 (Ref) 0.02 0.33 (Ref) 0.16
Family and/or friends discourage -0.34 (***) 0.02 -0.46 (***) 0.03 -0.41 (**) 0.19
Your doctor recommends 0.18(***) 0.02 0.40 (***) 0.02 0.50 (***) 0.15
Your doctor discourages -0.47 (***) 0.02 -0.75 (***) 0.03 -1.05 (***) 0.28
Government and public health institutions recommend 0.44 (***) 0.02 0.52 (***) 0.02 0.35 (**) 0.17
International organisations recommend 0.40 (***) 0.02 0.42 (***) 0.02 0.27 (*) 0.15
Traditional media is positive (reference) 0.03 (Ref) 0.01 0.22 (Ref) 0.02 0.33 (Ref) 0.12
Traditional media is negative -0.12 (***) 0.02 -0.22 (***) 0.00 -0.41 (***) 0.15
Social / interactive media is positive 0.12 (***) 0.02 0.18 (***) 0.00 0.22 (*) 0.12
Social / interactive media is negative -0.02 (NS) 0.02 -0.18 (***) 0.00 -0.14 (NS) 0.14
Out-of-pocket costs of the vaccine (per 10 euros) -0.04 (***) 0.00 -0.13 (***) 0.00 -0.14 (***) 0.02
Interaction: effectiveness of vaccine (per 10%) x 
susceptibility to the disease (per 100 of 1,000 persons) 0.07 (***) 0.01 0.12 (***) 0.00 0.12 (***) 0.02
Interaction: effectiveness of vaccine (per 10%) x severity of 
the disease (per 10%) 0.01 (***) 0.00 0.02 (***) 0.00 0.01 (**) 0.00
Class membership modele 
Constant -0.08 (NS) 0.10 0.00 (NA) 0.00 -0.83 (***) 0.13
The Netherlands (reference) 0.00 (Ref) 0.00 0.00 (Ref) 0.00 0.00 (Ref) 0.00
Poland 0.64 (***) 0.15 0.00 (NA) 0.00 0.07 (NS) 0.20
Spain 0.60 (***) 0.15 0.00 (NA) 0.00 0.12 (NS) 0.19
Sweden -0.09 (NS) 0.16 0.00 (NA) 0.00 0.86 (***) 0.17
Class probabilityf Proportion (RR) Proportion (RR) Proportion (RR) 
Average 0.44 (1.00) 0.35 (1.00) 0.21 (1.00)
Respondents from the Netherlands 0.39 (0.89) 0.42 (1.21) 0.18 (0.86)
Respondents from Poland 0.55 (1.24) 0.31 (0.89) 0.14 (0.69)
Respondents from Spain 0.53 (1.20) 0.32 (0.90) 0.16 (0.74)
Respondents from Sweden 0.30 (0.67) 0.35 (0.99) 0.36 (1.70)
Model fitg,h 
Akaike Information Criterion (AIC) 1.54
Pseudo-R2 0.30
SE: standard error; NA: not applicable; NS: non-significant coefficient; Ref: reference; RR: relative risk.
a Effects coded variables used for the safety of the vaccine, advice about the vaccine, media attention about the vaccine.
b The values of the vaccination programme attributes’ reference levels equals the negative sum of the coefficients of the included attribute.
c ***, **, * denotes significance at the 1% and 5% and 10% level respectively.
d Note that for class 2 and 3, the recommendation of family and/or friends had a negative effect on utility. However, the utility is still positive 
compared with discouraging of family and/or friends.
e Class 2 does not have parameters in the class membership model as the parameters of class 1 to 3 are relative to class 2.
f The relative risks represent the relative probability of someone belonging to that class compared with the average class probability.
g Note that the pseudo-R2 is not the same as the R2 that is used in a linear regression model. A pseudo-R2 of 0.3–0.4 is equivalent to a R2 
between 0.6 and 0.8 [21].
h A model with 3 classes is presented in the Table. This model had significantly better fit compared with a model with 2 classes (AIC: 1.64, 
pseudo-R2: 0.26). Although a latent class model with 4 classes had an improved fit (AIC: 1.50, pseudo-R2: 0.32), we opted for a model with 3 
classes to be able to explain the results to policymakers in a clear manner.
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sign of the coefficient reflects whether this impact has 
a positive or negative effect. Note that pandemic sce-
nario variables could only be included as an interac-
tion effect, as the scenario was the same in the three 
alternatives presented in each choice set. Several 
types of discrete choice models can be estimated. We 
chose a latent class model, since this is a closed form 
model (i.e. does not rely on complex simulations) that 
can take the panel nature of the data into account (i.e. 
dependencies between choice observations by a single 
respondent) [34].
A latent class analysis assumes the existence of sub-
groups (i.e. classes) of respondents with homogenous 
preferences. The researcher pre-specifies the num-
ber of classes based on the best model fit using the 
Akaike Information Criterion (AIC) and sound inter-
pretation of classes. Class membership is latent in 
that the researcher does not determine who belongs 
to which class a priori. Instead, class membership is 
expressed by class probabilities that may depend on 
the respondent’s characteristics. In addition to the 
choice model, we fitted a class membership model to 
test whether class membership is dependent on coun-
try of residence. Using the output of the class member-
ship model, the class probabilities adjusted for country 
of residence can be calculated.
Calculation of the relative importance of the attributes 
enables a direct comparison of preferences between 
classes. The percentages represent the proportion of 
someone’s preference (utility) that is based on that 
attribute. The relative importance can be calculated by 
dividing the difference in coefficient values between 
the highest and lowest level for a single attribute by the 
sum of the differences of all attributes for that class, 
considering interaction effects [35]. The mean expected 
uptake of a vaccine per class was calculated by taking 
the exponent of the total utility for vaccination divided 
by the exponent of utility of both vaccination and no 
vaccination. We were able to calculate these uptakes 
per country, by weighing the class-specific uptake with 
the class probabilities per country. The relative impor-
tance of the attributes and the expected vaccination 
uptake were calculated for two pandemic scenarios: a 
mild scenario in which 5% of the population gets the 
disease (susceptibility to the disease), and 5% of the 
sick people developing severe symptoms (severity of 
the disease), and a severe scenario in which 20% of 
the population gets the disease, and 75% of the sick 
people develops severe symptoms.
We used NLogit 4.0 software to estimate the latent 
class model and SPSS 21.0 software for all other analy-
ses, such as chi-squared tests to compare proportions 
between countries.
Results
Study population
In total 7,272 panel members were invited to par-
ticipate in the study. Of these, 2,651 started the sur-
vey (response rates ranged from 29% (627/2,186) for 
Spanish panel members up to 63% (677/1,083) for Dutch 
panel members; Figure 1). Of those who started, 2,068 
completed the survey, ranging from 73% (510/698) 
of Swedish panel members up to 82% (512/627) of 
Spanish panel members. The country samples were 
approximately representative regarding age, sex, edu-
cational level and region (Table 3). However, compared 
with national census data, lower educated Poles were 
slightly underrepresented as well as respondents from 
the western region of Spain.
Respondents took a mean of 19 min (standard devia-
tion: 31 min) to complete the survey. The majority of 
the respondents indicated that the survey topic was 
interesting or very interesting (81%; 1,677/2,068), and 
clear or very clear (74%; 1,528/2,068). A minority of 
respondents (9%; 179/2,068) found the survey hard 
or very hard to complete (ranging from 5% (28/510) 
for Poland to 13% (72/536) for the Netherlands). The 
proportion of choice sets in which the ‘no vaccination’ 
alternative was chosen was highest in the Swedish 
sample (51%; 4,145/(16*510=8,160)). The proportion 
of respondents that chose the ‘no vaccination’ alterna-
tive in all 16 choice sets was also higher in the Swedish 
sample (27% (136/510), p < 0.01) than elsewhere (10% 
for Poland (52/510) and Spain (54/512), and 11% 
(61/536) for the Netherlands). Additionally, the propor-
tion of respondents that always opted for vaccination 
was lowest in the Swedish sample (16%; 81/510), and 
highest in the Spanish sample (31%; 161/512).
Latent class analysis
Three latent classes, numbered from one to three, 
were identified (Table 4). The average class probability 
was 0.44, 0.35 and 0.21, for class 1, 2, and 3 respec-
tively. The country of residence partly explains class 
membership, which is an indication for preference 
heterogeneity between countries. Respondents from 
Poland and Spain had a significantly higher chance to 
belong to class 1 (0.55 and 0.53 respectively, p < 0.01) 
than respondents from other countries, those from the 
Netherlands had a significantly higher chance to belong 
to class 2 (0.42, p < 0.01), and those from Sweden to 
class 3 (0.36, p < 0.01).
Irrespective of the class they belonged to, respondents 
preferred a more effective vaccine that is expected 
to be safe, recommended by others, discussed posi-
tively in the media and with lower out-of-pocket costs, 
as can be seen by the positive and negative signs of 
the coefficients. The significant constant in all three 
classes indicates that, without considering any vac-
cination programme attributes, respondents of class 
2 and 3 had a rather negative attitude towards vac-
cination, while respondents belonging to class 1 did 
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not. Almost all vaccination programme attributes were 
significant. The positive recommendation of inter-
national organisations did not significantly explain 
preferences of respondents within class 3. The coef-
ficient for social/interactive media attention was not 
significantly different from positive traditional media 
attention for respondents of class 3 (both positive and 
negative social/interactive media attention) and class 
1 (only negative social/interactive media attention), 
meaning that social media only marginally influences 
respondents’ preferences for vaccination. Significant 
interaction effects between both susceptibility to and 
severity of the disease, and effectiveness of the vac-
cine in all classes indicate that the preference for the 
level of effectiveness of a vaccine is dependent on the 
seriousness of the pandemic. In other words, the more 
serious the pandemic, while the effectiveness of a vac-
cination remains the same, the more the preference for 
vaccination increases relative to no vaccination.
Relative importance
In the case of a mild scenario, the two most impor-
tant attributes for class 2 and 3 were advice regarding 
vaccination and out-of-pocket costs, while effective-
ness of the vaccine and advice regarding vaccination 
were the most important attributes for class 1 (Figure 
2). Although advice regarding vaccination was impor-
tant irrespective of class membership, for respondents 
belonging to class 3, the advice of friends and/or fam-
ily and the advice of physicians were most important 
for vaccination choice (based on differences between 
coefficients of advice regarding vaccine), while the 
advice of both national and international health 
authorities was important for respondents belonging 
to class 1. Additionally, all respondents were more sen-
sitive to advice against compared with advice in favour 
of vaccination. The relative importance of attributes 
varied with the seriousness of the pandemic scenario. 
Effectiveness was the most important attribute in the 
case of a severe scenario in all the latent classes and 
not only for respondents from class 1.
Predicted vaccine uptake
Assuming a realistic vaccination programme (i.e. a vac-
cination that is 70% effective, expected to be safe, 
recommended by family and/or friends, positively 
discussed in traditional media, and without out-of-
pocket costs), the mean expected uptake in the case 
of a mild scenario was lowest for Swedish respond-
ents with 43% (220/510; 95% confidence interval 
(CI): 40–47%)), followed by 54% (292/536; 95% CI: 
51–58%) for Dutch respondents, 62% (318/512; 95% 
CI: 59–65%) for Spanish respondents, and highest for 
respondents from Poland with 63% (323/510, 95% CI: 
60–66%). In the case of a mild scenario, advice regard-
ing the vaccine and out-of-pocket costs had a relatively 
large impact on vaccination uptake in all countries, 
while media attention had little effect on uptake. For 
example, when out-of-pocket costs increased from 0 
to 100 euros, the uptake decreased to 32% (163/510; 
95% CI: 29–35%) for Swedish respondents, followed 
by 41% (222/536; 95% CI: 38–45%) for Dutch respond-
ents, 51% (263/512; 95% CI: 48–55%) for Spanish 
respondents, and 53% (269/510; 95% CI: 49–56%) for 
Polish respondents. The uptake rates were expected 
to increase dramatically in the case of a severe sce-
nario with up to 65% (331/510; 95% CI: 61–69%) for 
respondents from Sweden, and 82% (419/510; 95% CI: 
80–85%) for respondents from Poland.
Discussion
Statement of principal findings
In the case of a severe pandemic scenario, vaccine 
effectiveness was the most important characteristic 
determining vaccination preference in all countries. 
The body that advises a vaccine was found to strongly 
affect preferences in all countries as well, with respond-
ents being more sensitive to advice against compared 
with advice in favour of vaccination. Preference het-
erogeneity between countries was substantial, espe-
cially in the case of a mild pandemic scenario; a strong 
effect on vaccine preferences was found for the advice 
of family and/or friends and the advice of physicians 
in Sweden, in contrast to Poland and Spain, where 
the advice of (international) health authorities was 
more important. Besides the vaccination advice, out-
of-pocket costs were important for Dutch and Swedish 
respondents, while for respondents from Poland and 
Spain the effectiveness of the vaccine was important in 
case of a mild pandemic scenario. Irrespective of pan-
demic scenario or programme attributes, the predicted 
vaccination uptakes were lowest in Sweden, and high-
est in Poland.
Strengths and weaknesses of the study
So far, only a limited number of healthcare-related 
DCEs have quantitatively compared preferences 
between respondents from different countries and this 
is, to our best knowledge, done for the first time in the 
field of infectious diseases. An additional strength is 
the advanced analysis technique we used in this study. 
While already used extensively in the field of transport 
economics, latent class analysis has been used for 
only 3% of all health-related DCE analyses conducted 
between 2009 and 2012 [23]. A possible weakness of 
our study is that the preferences are stated and based 
on hypothetical pandemic scenarios. Respondents 
might have given socially desirable responses. It is 
not known to what extent the stated preferences differ 
from preferences during an actual pandemic. However, 
the external validity of the DCE method has been stud-
ied in other health related contexts, and results are 
encouraging with respect to prediction of preferences 
on an aggregate level [36,37]. In addition, the hypo-
thetical nature of the study enabled us to compare pref-
erences between different possible future pandemic 
scenarios. The findings might thus help to prepare for 
a future pandemic. Additionally, all coefficients had 
the expected sign, which suggests theoretical valid-
ity of the DCE [38]. Another possible weakness is the 
complexity of the choice sets, due to inclusion of risks 
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as attributes. However, we thoroughly pilot tested the 
survey and, during the online survey, only a minority 
of respondents stated that they experienced problems 
completing the choice sets.
Results in relation to other studies
Our study showed that the expected vaccination 
uptake is largely dependent on the seriousness of 
a pandemic. This was also shown in previous stud-
ies, including studies conducted in the Netherlands, 
Poland, Spain and Sweden [39-45]. During the influ-
enza A(H1N1)pdm09 pandemic, the perceived vulner-
ability was low and respondents believed that they 
were less likely to become infected than other people 
[41,46]. This might have been one of the reasons for 
the lower than expected uptake during that pandemic 
with overall, 30%, 27% and 59% of the Dutch, Spanish 
and Swedish population respectively, having been vac-
cinated (Table 1). Interestingly, we found that Swedish 
respondents were least willing to get vaccinated in 
future influenza pandemics, both in mild and severe 
scenarios. As previous experiences are likely to influ-
ence future vaccination uptake [45], the difference 
between our study results and actual influenza A(H1N1)
pdm09 vaccination coverage might be assigned to the 
negative experiences Swedish citizens had with vac-
cination during the 2009 pandemic. In Sweden, the 
controversy on the association between pandemic 
vaccines and narcolepsy is still ongoing [47]. In addi-
tion, Swedish respondents in the current study less 
often had received seasonal influenza vaccination in 
the previous year compared with e.g. Dutch respond-
ents (41% vs 65%, Table 3). Research, conducted in the 
Netherlands, has shown that trust in health authorities 
is related to pandemic influenza vaccination uptake 
[48] and that it is necessary to build up and sustain 
trust before, during and after an influenza pandemic 
[16]. Furthermore, during the influenza A(H1N1)pdm09 
pandemic Dutch and Swedish participants had more 
trust in healthcare professionals compared with Polish 
and Spanish participants [18]. Our research shows the 
same inter-country differences. Poland did not imple-
ment a national vaccination programme during the 
influenza A(H1N1)pdm09 pandemic [15,44] (Table 1). 
Seasonal influenza vaccination coverage is reported to 
be less than 10% for the target population older than 
55 years [49]. Reported reasons for the Polish pub-
lic to reject influenza (both seasonal and pandemic) 
vaccination include the low level of confidence in the 
quality and effectiveness of the vaccine [18,50]. Our 
finding that effectiveness of a pandemic vaccine had 
by far the strongest effect on vaccination choice of 
Polish respondents, confirmed this. The lowest sea-
sonal influenza vaccination coverage contrasts with 
our finding that Polish respondents were more willing 
to get vaccinated than respondents from other coun-
tries. However, in our study, the level of effective-
ness of the vaccine was presented to respondents as 
a known rate, which might explain why we estimated 
a higher vaccination uptake. Safety of the pandemic 
vaccine was not as dominant in the current study as in 
other studies [39,40]. The choice of attribute levels for 
our DCE might explain this difference in relative impor-
tance. We included realistic attribute levels, instead of 
presenting a certain vaccination risk (e.g. 1 in 100,000) 
to respondents. We also analysed safety as an inter-
action with the pandemic scenario variable ‘severity 
of the disease’, but with no meaningful outcome. We 
found almost no effect of social media attention (com-
pared to traditional media) on pandemic vaccination 
preferences and predicted uptake. The objective fram-
ing of this attribute in the DCE survey might explain the 
finding. However, social media will likely be influential 
in future pandemics in other ways, e.g. by creating 
online applications that provide credible health infor-
mation [51].
Implications for clinicians and policymakers
Our results show that seriousness of a pandemic influ-
ences vaccination uptake dramatically. In order to 
increase pandemic vaccination coverage, it is essential 
that susceptible people feel susceptible and perceive 
the pandemic as a serious threat. This can be achieved, 
for example, by honest and open communication 
regarding the seriousness of the pandemic, and avoid-
ing conflicting messages and information overload 
[17,52] and by providing public health messages that 
include descriptive and injunctive normative informa-
tion [53,54]. The WHO Regional Office for Europe and 
the European Centre for Disease Prevention and Control 
(ECDC) recommend more flexible pandemic prepared-
ness planning, i.e. planning that takes into account 
different pandemic scenarios [8,9,19]. Findings of our 
study may facilitate responses to future influenza pan-
demics with different levels of severity, as our study 
provides the option to calculate the expected vaccina-
tion uptake for different pandemic scenarios, and pro-
vides insights into how several vaccination programme 
attributes influence these uptakes. Additionally, our 
study also shows that the availability of an effective 
pandemic vaccine is of paramount importance in order 
to reach certain coverage levels. Unfortunately, such a 
highly effective vaccine might not be available due to 
the crisis situation that is inherent to a pandemic, or 
proof that the vaccine is effective might be lacking as 
time is usually limited. In addition, due to contracts or 
limited availability of vaccines, there are usually only 
one or two different vaccines available for policymak-
ers to choose from. For all countries, given the high 
impact of vaccine effectiveness on vaccination prefer-
ences, it is therefore important that there is open com-
munication regarding the expected effectiveness, so 
that the public can make an informed choice whether 
to get vaccinated or not. The vaccination programme 
attributes that can be influenced by policymakers 
directly are out-of-pocket costs and how/what to com-
municate. As our results show that by whom a vac-
cine is advised had a different effect on uptake in the 
included countries, it is important that during future 
pandemics the responsible authorities align with other 
important stakeholders in the country and communi-
cate in a coordinated manner.
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Unanswered questions and further research
We found different in preferences for pandemic vac-
cinations between difference European countries. 
Further research could focus on differences within 
these countries, e.g. whether preferences of those who 
previously received seasonal influenza vaccination dif-
fer from preferences of those who had not, as previous 
research shows that the uptake of seasonal influenza 
vaccination was positively associated with influenza 
A(H1N1)pdm09 vaccination decision-making [39,55,56]. 
Additionally, future research could focus on subgroups 
of the population, such as healthcare workers or under-
vaccinated groups. It is unknown whether preferences 
differ between countries within the same geographi-
cal area of Europe. Therefore, it might be useful to 
conduct the same DCE in other European countries as 
well. Unfortunately, timely access to vaccinations is 
not self-evident [57]. It is not known in advance which 
respiratory pathogen will cause a next pandemic and 
production capacities might be inadequate. In the case 
of an influenza pandemic, other preventive measures 
such as quarantine, and antiviral drugs might be help-
ful to limit the spread of the virus during the first phase 
[10]. Further research into preferences for other preven-
tive measures, and differences herein across European 
countries, using the DCE methodology is thus recom-
mended. Moreover, the DCE methodology could also 
be used to study motivations and barriers for vaccina-
tions other than pandemic vaccination among different 
countries.
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